Expert consensus on polypharmacy for respiratory diseases guided by genetic polymorphism
Multi-drug combination therapy is frequently used in patients with respiratory diseases.Affected by common drug metabolism enzymes or transporters,multi-drug use is prone to produce drug interactions,which can affect efficacy or lead to adverse drug reactions.The activity of drug metabolism enzymes and transporters and the sensitivity of drug targets are affected by genetic factors,resulting in individual differences in drug efficacy.Therefore,individualized medication regimen adjustment by detecting genes related to drug metabolism combined with clinical efficacy evaluation has gradually become an important means for the risk prevention and control of multi-drug use in clinical multi-disease comorbidities.The Clinical Pharmacy Branch of the Chinese Medical Association organized relevant experts to formulate the Expert Consensus on Multi-drug Use for Respiratory Diseases under the Guidance of Gene Polymorphism based on the latest evidence-based medical or pharmacy results for patients with multiple-drug use for respiratory tract diseases,further promoting its application in the treatment practice of respiratory system clinical diseases,and providing evidence support for medical institutions to make clinical treatment plans.
国家科技期刊平台
NSTL
万方数据
